logo
InnovationRx: Trump's EU Tariff Deal Will Add $13 Billion To Drug Costs

InnovationRx: Trump's EU Tariff Deal Will Add $13 Billion To Drug Costs

Forbes30-07-2025
In this week's edition of InnovationRx, we look at the impact of Trump's tariffs on drugs made in Europe, Halle Berry's menopause startup, Ambience Healthcare's $243 million fundraise, and more. To get it in your inbox, subscribe here .
Eli Lilly's plant in Kinsale, Ireland Bloomberg Finance
F or months, there have been questions about what the impact of Trump's tariffs on drugs would be. On Sunday, we got part of the answer: Under the trade deal reached between the U.S. and the European Union, medicines imported from Europe will face a 15% tariff.
That tax hike will hit some of the biggest blockbuster drugs, including Keytruda (for cancer) and Wegovy (for obesity), as well as less well-known brand name medications. Questions remain about generics: European Commission President von der Leyen said on Sunday that certain generics would be exempt, but the White House fact sheet on the deal lists no such exceptions.
What is clear, though, is that the cost of the tariff will likely be passed to American consumers, both directly and indirectly through higher insurance premiums. ING analyst Diedrick Stadig told Forbes that once stockpiled medicines are gone, the tax would add around $13 billion to the cost of imported drugs.
There will be indirect costs, too. As companies look to manage the impact of Trump's tariffs by building out U.S. manufacturing, they could potentially cut spending in other areas, including research and development, to compensate, Emarketer analyst Rajiv Leventhal told Forbes . 'They're going to have to cut back in other areas to not have Wall Street panic,' he said.
Halle Berry Cliff Watts for Forbes
In May 2024, Halle Berry, the actress and former model, shouted three words on Capitol Hill to a bipartisan group of senators (all women): ' I'm in menopause! '
Berry, now 58, first became focused on the issue, as both an entrepreneur and an advocate, after her own perimenopause was misdiagnosed as herpes. She originally founded Respin as a wellness and exercise website in 2020, but relaunched it this February as a menopause-focused healthcare company.
With less than $5 million in funding from investors including Khosla Ventures, Respin is still in its earliest days. Telehealth visits just launched in July and revenue is mostly nonexistent. But Berry's work, profiled in Forbes as part of this year's 50 Over 50 list, is just one indication, along with VC-backed Midi Health, which has raised more than $100 million, that menopause is finally getting some attention.
'This is my greatest act,' Berry tells Forbes. 'And I couldn't have imagined that this would be my greatest act because I think as women, we've been afraid to age.'
Read more here. BIOTECH AND PHARMA
Sarepta Therapeutics is again shipping its gene therapy Elevidys for patients with Duchene muscular dystrophy (a particularly severe form of the disease) who are able to walk. The latest move came after the FDA recommended the removal of a voluntary hold it had previously placed on the drug. The face-off between Sarepta and the FDA followed the deaths of three people from Elevidys or a similar drug (that's in early-stage clinical trials) from liver failure. Duchenne patients and their families had put pressure on the FDA to reverse the decision, though the agency said it will continue to investigate the deaths.
On Tuesday night, Vinay Prasad, the FDA's top vaccine and gene therapy official, abruptly resigned after just three months after he took the job. Prasad, head of the Center for Biologics Evaluation and Research, had faced heavy criticism from the right over his handling of Sarepta, including an op-ed from The Wall Street Journal 's editorial board and derision from pro-Trump influencer Laura Loomer. The Health and Human Services Department has not yet said who will fill his role. DIGITAL HEALTH AND AI
Open AI-backed startup Ambience Healthcare raised $243 million – one of the year's largest VC investments in healthtech – led by Oak HC/FT and Andreessen Horowitz. The new funding increases Ambience's valuation to more than $1 billion, according to Bloomberg. Founders Michael Ng, the company's CEO, and Nikhil Buduma, its chief scientist, previously founded digital health startup Remedy Health.
Plus: Sword Health, the $4 billion (valuation) digital health startup, launched a new AI division to help payers and providers increase operational efficiency. MEDTECH
Imagine getting a heart valve replacement and being able to resume your normal, daily activities a week later. That's the reality for four patients at the Cleveland Clinic, according to case studies it presented earlier this year. Its surgeons were able to use robots to perform the aortic valve replacement surgery through the patients' necks, avoiding the need for open-heart surgery and its accompanying long, painful recovery. One patient even reported he'd resumed running in the gym a week after he was discharged. PUBLIC HEALTH AND HOSPITALS
Millions of undergraduate and graduate students rely on Medicaid for health coverage. As long as they attend school more than half-time, they should meet the new work requirement added in the recently passed 'One Big Beautiful Bill'. But yet-to-be issued rules and procedures, along with paperwork problems and administrative snafus, could still put many of them at risk. One big problem: The law doesn't actually define what 'half-time enrollment' means. Another: The law requires applicants to look back one month to see if they met the work requirement, and it's unclear what that means for a new student who was, for example, on summer break the month before they enrolled. This and many other unanswered questions will likely leave millions of college students' health insurance in limbo as the legislation is implemented. WHAT WE'RE READING
Some psychiatric patients may actually have treatable autoimmune conditions. The New Yorker explores the story of one schizophrenia patient who suddenly recovered.
Scientists are using AI to boost efforts to spot flags for diseases of extreme tiredness, including long COVID and chronic fatigue syndrome.
China is facing a major outbreak of the mosquito-borne disease chikungunya, which has infected more than 4,000 people.
White House officials scrapped a plan by the Office of Management and Budget that would have effectively halted NIH grants, and the funds are set to flow again.
Tribal health officials are working to fill in vaccination gaps as the U.S. measles outbreak continues to spread.
UnitedHealth Group's profit fell to $3.4 billion in the second quarter, from $4.2 billion in the same period last year, as it grapples with rising costs of providing health insurance to millions of Americans.
Shares of Novo Nordisk, which makes Wegovy and Ozempic, dropped more than 21% Tuesday, after it cut its guidance to analysts on sales and profit for the year. MORE FROM FORBES Forbes The Tech Mogul Behind Trump's Truth Social Used To Own Porn Domains By Emily Baker-White Forbes How The World's Second-Richest Person And His Son Pulled Off The $8 Billion Paramount Deal By Phoebe Liu Forbes Trump Has Spent About One-Third Of His Presidency Visiting His Own Properties By Dan Alexander
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Futures edge up as Fed shake-up stokes dovish bets
Futures edge up as Fed shake-up stokes dovish bets

Yahoo

time24 minutes ago

  • Yahoo

Futures edge up as Fed shake-up stokes dovish bets

(Reuters) -U.S. stock index futures rose on Friday after President Donald Trump's temporary pick for a Federal Reserve governor fueled expectations of a more dovish central bank board. Trump said on Thursday he would nominate Council of Economic Advisers Chairman Stephen Miran as Fed Governor Adriana Kugler's interim replacement, following Kugler's surprise resignation last week. U.S. stocks lost steam on Thursday after Bloomberg News reported that Fed Governor Christopher Waller is emerging as a top candidate to be the central bank's next chair. Trump has repeatedly criticized Fed Chair Jerome Powell for not cutting interest rates and has accelerated the search for a replacement after several retracted threats to oust Powell before his term ends on May 15. The White House's push to overhaul the central bank's leadership has fueled worries about its independence. At the same time, investors believe revising Fed leadership could favor looser monetary policy that aligns with Trump's agenda. According to the CME Group's FedWatch tool, traders broadly expect the Fed's first rate cut of the year next month and see at least two reductions by year-end. At 5:31 a.m. ET, S&P 500 E-minis were up 16 points, or 0.25%, Nasdaq 100 E-minis were up 72.25 points, or 0.31% and Dow E-minis were up 61 points, or 0.14%. The Nasdaq eked out a record closing high on Thursday after signs that major technology firms could avoid Trump's new tariffs on chip imports by manufacturing in the United States. But the S&P 500 and the Dow ended lower, weighed down by a 14.1% drop in Eli Lilly after results from a late-stage study on its experimental GLP-1 pill fell behind that of Novo Nordisk's. Meanwhile, U.S. tariffs on a bunch of trading partners took effect at midnight on Thursday. Tokyo's trade negotiator said Washington will amend a presidential executive order to remove overlapping tariffs on Japanese goods, terming it as oversight. In earnings-related moves, Trade Desk sank 29% in premarket trading after the ad-tech firm reported a sharp slowdown in second-quarter revenue growth. Pinterest tumbled 12.5% as the social media platform missed analysts' estimates for second-quarter profit. Microchip Technology lost 7.9% after the chipmaker's first-quarter results failed to impress investors. St. Louis Fed President Alberto Musalem is scheduled to speak later at 10:20 a.m. ET.

China narrows gap with US as Germany's biggest trading partner
China narrows gap with US as Germany's biggest trading partner

Yahoo

time24 minutes ago

  • Yahoo

China narrows gap with US as Germany's biggest trading partner

By Rene Wagner and Maria Martinez BERLIN (Reuters) -China came close to overtaking the United States as Germany's largest trading partner in the first half of 2025, preliminary data from the German statistics office showed, as German exports to the U.S. declined amid higher tariffs. German imports and exports with the U.S. totalled about 125 billion euros ($145 billion) from January to June, while trade with China reached 122.8 billion euros, according to Reuters calculations. "Although the U.S. was able to defend its position as Germany's most important trading partner, the lead over German trade with China is razor-thin," said Vincent Stamer, economist at Commerzbank. The U.S. had overtaken China as Germany's top trading partner in 2024, ending an eight-year streak for China. The shift came as Germany sought to reduce its reliance on China, with Berlin citing political differences and accusing Beijing of unfair practices. Trade dynamics shifted again, however, in 2025 with Donald Trump's return to the White House and renewed tariffs. The EU's trade deal with the U.S. in July set tariffs at 15% for most products. 'As the year progresses, losses in German exports to the U.S. are likely to continue and even intensify,' said Juergen Matthes, head of international economic policy at the Cologne Institute for Economic Research. German exports to the U.S. fell 3.9% to 77.6 billion euros in the first half compared to the same period last year. Commerzbank expects new U.S. tariffs to slow Germany's exports to the U.S. by 20% to 25% over the next two years. 'As a result, China is likely to regain the top spot among Germany's trading partners over the course of the year,' Stamer said. CHINESE IMPORTS SURGE Imports from China surged 10.7% year-on-year in the first half, reaching 81.4 billion euros. 'Apparently, German companies and consumers find it difficult to replace Chinese goods,' Stamer said. The rise may indicate China has begun redirecting trade from the U.S. to Europe, flooding the German and European market with cheaper goods, said Carsten Brzeski, global head of macro at ING. A significant undervaluation of the yuan against the euro is also making Chinese imports cheaper, said Cologne Institute's Matthes. German exports to China fell 14.2% to 41.4 billion euros, with exporters struggling amid increased competition from Chinese manufacturers. The sharp decline in exports to China, combined with surging imports, has led to a record trade deficit of 40 billion euros, second only to 2022. 'All these developments are damaging the German economy and further exacerbating the industrial crisis,' Matthes said. ($1 = 0.8600 euros) Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data

Agora, Inc. to Report Second Quarter 2025 Financial Results on August 18, 2025
Agora, Inc. to Report Second Quarter 2025 Financial Results on August 18, 2025

Yahoo

time24 minutes ago

  • Yahoo

Agora, Inc. to Report Second Quarter 2025 Financial Results on August 18, 2025

SANTA CLARA, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Agora, Inc. (NASDAQ: API), a pioneer and leader in conversational AI and real-time engagement technology, will release its financial results for the second quarter ended June 30, 2025 after the close of U.S. markets on August 18, 2025. Agora, Inc. will host a conference call to discuss the financial results at 6 p.m. Pacific Time / 9 p.m. Eastern Time on the same day. Details for the conference call are as follows: Event title: Agora, Inc. 2Q 2025 Financial Results The call will be available at Investors who want to hear the call should log on at least 15 minutes prior to the broadcast. Participants may register for the call with the link below. Please visit Agora, Inc.'s investor relations website at on August 18, 2025 to view the earnings release and accompanying slides prior to the conference call. About Agora, Inc. Agora, Inc. is the holding company of two independent businesses, Agora and Shengwang. Headquartered in Santa Clara, California, Agora is a pioneer and global leader in conversational AI and Real-Time Engagement Platform-as-a-Service (PaaS), providing developers with simple, flexible, and powerful application programming interfaces, or APIs, to embed real-time conversational AI, video, voice, chat and interactive streaming into their applications. Headquartered in Shanghai, China, Shengwang is a pioneer and leading conversational AI and Real-Time Engagement PaaS provider in the China market. For more information on Agora, please visit: more information on Shengwang, please visit: CONTACT: Investor Contact: investor@ Media Contact: press@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store